Brassard Liliane, Bessette Paul
Service d'obstétriq ue-gynécologie, Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke (Québec).
J Obstet Gynaecol Can. 2012 Jul;34(7):657-63.
To determine the value of gynaecological cytology and CA 125 level in preoperatively predicting extrauterine malignancy in endometrial cancer.
This retrospective study evaluated 225 women with endometrial cancer that underwent surgery between January 1996 and January 2010 at the Centre hospitalier universitaire de Sherbrooke. CA 125 level, gynaecological cytology, and histopathological data were available for each patient. Statistical analyses relied on chi-square test and Fisher exact test, as well as on a multivariable logistical regression model.
At diagnosis, 163 patients (72.5%) presented with a stage 1 malignancy. A correlation between bad prognosis histopathological factors (grade 3, lymphovascular invasion and myometrial invasion ≥ 50%, lymph-node metastases at histology: clear cell, seropapillary and undifferentiated, P = 0.05) and the combination of an increased CA 125 level (≥ 35 U/mL) and an abnormal gynaecological cytology (glandular anomalies) was discovered. Moreover, an extrauterine malignancy is found in 69.4% of patients with an increased CA 125 level and an abnormal gynaecology cytology, compared to 19.6% of patients with normal results (P < 0.001). According to multivariate analyses of preoperative factors, the combination of these two tests is the most powerful predictor of extrauterine malignancy in endometrial cancer (OR 9.3; 95% CI 4.2 to 20.7). When both results are found to be preoperatively abnormal, final histopathology analysis will reveal the presence of an extrauterine malignancy in 49.1% to 83.2% of patients.
The preoperative evaluation of women with endometrial cancer should include routine evaluation of CA 125 level and routine gynaecological cytology, since the combination of these two tests offers crucial data on the probability of a stage FIGO ≥ 2 illness thus facilitating preoperative triage of high risk patients. A pelvic or para-aortic lymphadenectomy should be offered to patients with increased CA 125 level and abnormal gynaecological cytology by a competent professional.
确定妇科细胞学检查及CA 125水平在术前预测子宫内膜癌子宫外恶性病变中的价值。
这项回顾性研究评估了1996年1月至2010年1月期间在舍布鲁克大学中心医院接受手术的225例子宫内膜癌女性患者。每位患者均有CA 125水平、妇科细胞学检查及组织病理学数据。统计分析采用卡方检验、Fisher精确检验以及多变量逻辑回归模型。
诊断时,163例患者(72.5%)为Ⅰ期恶性肿瘤。发现预后不良的组织病理学因素(3级、淋巴管浸润、肌层浸润≥50%、组织学检查有淋巴结转移:透明细胞癌、浆液性乳头状癌及未分化癌,P = 0.05)与CA 125水平升高(≥35 U/mL)及妇科细胞学检查异常(腺性异常)之间存在相关性。此外,CA 125水平升高且妇科细胞学检查异常的患者中,69.4%发现有子宫外恶性病变,而结果正常的患者中这一比例为19.6%(P < 0.001)。根据术前因素的多变量分析,这两项检查的联合是子宫内膜癌子宫外恶性病变最有力的预测指标(比值比9.3;95%可信区间4.2至20.7)。当术前两项结果均异常时,最终组织病理学分析将显示49.1%至83.2%的患者存在子宫外恶性病变。
子宫内膜癌女性患者的术前评估应包括CA 125水平的常规评估及常规妇科细胞学检查,因为这两项检查的联合可为FIGO分期≥2期疾病的可能性提供关键数据,从而有助于对高危患者进行术前分诊。对于CA 125水平升高且妇科细胞学检查异常的患者,应由专业人员进行盆腔或腹主动脉旁淋巴结清扫术。